CD388 is now a cleaner Phase 3 bet
- Cidara is now mainly a bet on CD388, a long-acting flu prevention shot in Phase 3 testing.
- The FDA granted Breakthrough Therapy designation to CD388 in October 2025, after positive Phase 2b data.
- The Phase 3 ANCHOR study started in September 2025, six months ahead of prior guidance.
- BARDA can provide up to $339.2M, including $58.1M over 24 months to move manufacturing to the U.S.
- The main risk is simple: if ANCHOR fails or needs major changes, the stock thesis changes fast.
A faster, better funded CD388 story
Cidara has become a focused clinical-stage biotech. The company sold rezafungin in April 2024 and put its effort into Cloudbreak, its drug-Fc conjugate platform. A drug-Fc conjugate, or DFC, is meant to hit a disease target while also using part of an antibody to last longer in the body.
The bull case got stronger in late 2025. CD388 received FDA Breakthrough Therapy designation, the Phase 3 ANCHOR study started in September 2025, and the company said the study was over 50 percent enrolled by early November 2025. Cidara also signed a BARDA agreement with up to $339.2M in potential funding, with the first $58.1M aimed at moving CD388 manufacturing to the U.S.
The bear case is still real. Cidara has no approved Cloudbreak product and depends heavily on one asset. A positive Phase 2b result lowers risk, but it does not remove Phase 3 risk. The company also needs to decide how CD388 would be sold if approved, either with a partner or with its own commercial buildout.
There is also an open timing question because some key events expected after the Q3 2025 filing, such as full ANCHOR enrollment and interim sizing work, are not resolved in the internal filing record used for this page. Until those outcomes are confirmed in company filings or releases, Finn treats them as watch items, not closed facts.
No sales yet, value from trial success
Cidara does not have a commercial Cloudbreak product today. Its business model is to create DFC drugs, prove them in trials, then make money through future product sales, partnerships, licenses, or larger drug-company collaborations.
CD388 is the center of the model. It is being tested as a one-time 450-milligram subcutaneous dose to prevent influenza A and B in adults and adolescents. If it works in Phase 3, Cidara could try to sell it itself, but a partner may be more practical because flu prevention needs large sales, access, and supply systems.
The BARDA contract matters because it is non-dilutive funding, meaning Cidara does not have to sell stock to receive it. The base period provides an estimated $58.1M over 24 months for U.S. manufacturing work, and total potential funding is up to $339.2M if options are exercised.
Where the model can break is clear. A failed Phase 3 trial, a slow manufacturing transfer, or a weak commercial plan would all hurt the path from science to revenue.
One lead asset, one platform option
CD388
CD388 is the lead Cloudbreak DFC for prevention of seasonal and pandemic influenza A and B. It is now in the global Phase 3 ANCHOR study.
ANCHOR Phase 3 study
ANCHOR is the main value driver because it tests whether CD388 can prevent flu in a pivotal setting. Cidara expected target enrollment of 6,000 participants by December 2025 in the Northern Hemisphere.
Cloudbreak platform
Cloudbreak is Cidara's DFC technology base. The platform could matter beyond flu, but investors are mostly paying for CD388 right now.
CBO421
CBO421 is a CD73-targeting DFC for solid tumors with IND clearance from July 2024. Cidara does not plan to start trials now and is seeking business development options.
One reported operating segment
Cidara reports one operating segment: research and development of DFCs from Cloudbreak. The split below treats Cloudbreak R&D as the whole active business and shows no current commercial product sales.
What can still go wrong
ANCHOR trial miss
High impact · Medium oddsCidara's value depends heavily on CD388. Positive Phase 2b data helped, but Phase 3 studies can still fail, need more patients, or show safety issues. Any major delay would likely reset investor expectations.
China supply chain exposure
High impact · Medium oddsThe Q3 2025 filing says CD388 was still made through WuXi XDC and affiliates in China. Cidara also cites possible U.S. laws such as the BIOSECURE Act as a risk. The BARDA plan directly helps, but tech transfer is long and can fail.
Commercial funding gap
High impact · Medium oddsCidara had $476.5M in cash, cash equivalents, and restricted cash as of September 30, 2025, enough to fund the planned Phase 3 study. That does not mean it can launch CD388 alone. A flu prevention product needs scale, payor access, sales reach, and inventory.
Flu market adoption
Medium impact · Medium oddsCD388 would compete with flu vaccines and antiviral drugs. Even if approved, doctors, payors, and public-health buyers must see a clear reason to use it. The strongest fit may be people who respond poorly to vaccines or cannot take them.
Oncology stays stranded
Low impact · Medium oddsCBO421 is not the main reason to own the stock today. Cidara has IND clearance but does not plan to start trials now. If no partner appears, this program may stay parked.
In one breath
What does Cidara Therapeutics do?
Cidara develops drug-Fc conjugates from its Cloudbreak platform. Its lead program is CD388, a long-acting flu prevention candidate in Phase 3 testing.
Is CD388 a vaccine?
No. CD388 is designed as a non-vaccine flu prevention medicine. It aims to protect people with a single subcutaneous dose rather than by training the immune system like a vaccine.
Why does BARDA funding matter for Cidara?
BARDA can provide up to $339.2M if all options are used. The first $58.1M is meant to help move CD388 manufacturing to the U.S., which directly addresses a major supply chain risk.
What is the biggest thing to watch next?
The key watch item is the Phase 3 ANCHOR trial. Investors should look for enrollment completion, interim analysis results, safety updates, and whether the study can support a future approval filing.